CL2019001891A1 - Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas. - Google Patents

Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.

Info

Publication number
CL2019001891A1
CL2019001891A1 CL2019001891A CL2019001891A CL2019001891A1 CL 2019001891 A1 CL2019001891 A1 CL 2019001891A1 CL 2019001891 A CL2019001891 A CL 2019001891A CL 2019001891 A CL2019001891 A CL 2019001891A CL 2019001891 A1 CL2019001891 A1 CL 2019001891A1
Authority
CL
Chile
Prior art keywords
disease
protein aggregation
heteroaryl derivatives
parkinother
reverse
Prior art date
Application number
CL2019001891A
Other languages
English (en)
Inventor
Laurent Provins
Adrian Hall
Malcolm Maccoss
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2019001891A1 publication Critical patent/CL2019001891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON CIERTOS COMPUESTOS BIS-HETEROARILO BICÍCLICOS DE FÓRMULA (I), LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y LOS MÉTODOS PARA USARLOS, INCLUIDOS LOS MÉTODOS PARA PREVENIR, REVERTIR, DESACELERAR O INHIBIR LA AGREGACIÓN DE PROTEÍNAS, Y LOS MÉTODOS PARA TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LA AGREGACIÓN DE PROTEÍNAS, INCLUIDAS ENFERMEDADES NEURODEGENERATIVAS COMO LA ENFERMEDAD DE PARKINSON, LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE CUERPOS DE LEWY, LA ENFERMEDAD DE PARKINSON CON DEMENCIA, LA DEMENCIA FRONTOTEMPORAL, LA ENFERMEDAD DE HUNTINGTON, LA ESCLEROSIS LATERAL AMIOTRÓFICA, LA ATROFIA MULTISISTÉMICA Y EL CÁNCER, INCLUIDO EL MELANOMA.
CL2019001891A 2017-01-26 2019-07-08 Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas. CL2019001891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17153217 2017-01-26

Publications (1)

Publication Number Publication Date
CL2019001891A1 true CL2019001891A1 (es) 2019-11-22

Family

ID=57906529

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001891A CL2019001891A1 (es) 2017-01-26 2019-07-08 Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.

Country Status (16)

Country Link
US (1) US10889584B2 (es)
EP (1) EP3573986B1 (es)
JP (1) JP7073385B2 (es)
KR (1) KR20190112022A (es)
CN (1) CN110167937B (es)
AU (1) AU2018212438C1 (es)
BR (1) BR112019011924A2 (es)
CA (1) CA3045221A1 (es)
CL (1) CL2019001891A1 (es)
CO (1) CO2019007830A2 (es)
EA (1) EA201991755A1 (es)
ES (1) ES2884145T3 (es)
IL (1) IL267993A (es)
MX (1) MX2019008256A (es)
RU (1) RU2019126167A (es)
WO (1) WO2018138088A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57533B1 (sr) 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10889584B2 (en) * 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
ES2918048T3 (es) * 2017-01-26 2022-07-13 UCB Biopharma SRL Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
EP4206200A1 (en) * 2020-08-25 2023-07-05 National Institutes for Quantum Science and Technology Novel compound, alpha-synuclein aggregate binder, and use thereof
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
BR112012014807A2 (pt) 2009-12-16 2017-06-27 Neuropore Therapies Inc "compostos adequados para o tratamento de sinucleopatias"
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
EP2830608B8 (en) 2012-03-28 2020-01-15 UCB Biopharma SRL Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
AU2013290361A1 (en) 2012-07-16 2015-02-05 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
RS57533B1 (sr) 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10889584B2 (en) * 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
AU2018212438A1 (en) 2019-07-25
KR20190112022A (ko) 2019-10-02
IL267993A (en) 2019-09-26
EA201991755A1 (ru) 2020-01-22
CO2019007830A2 (es) 2019-07-31
EP3573986B1 (en) 2021-05-26
ES2884145T3 (es) 2021-12-10
BR112019011924A2 (pt) 2019-10-29
US10889584B2 (en) 2021-01-12
CN110167937A (zh) 2019-08-23
WO2018138088A1 (en) 2018-08-02
JP2020505369A (ja) 2020-02-20
AU2018212438B2 (en) 2020-12-17
CA3045221A1 (en) 2018-08-02
JP7073385B2 (ja) 2022-05-23
RU2019126167A (ru) 2021-02-26
CN110167937B (zh) 2022-03-29
MX2019008256A (es) 2019-09-09
AU2018212438C1 (en) 2021-05-06
US20190367513A1 (en) 2019-12-05
EP3573986A1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019001752A1 (es) Derivados de bis-heteroarilo como moduladores de la agregación de proteínas.
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CO2018002060A2 (es) Compuestos farmacéuticos
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
ECSP17028463A (es) 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2017000117A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CO2019002889A2 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2019001512A1 (es) Tratamiento de enfermedades neurológicas.
AU2017251303B2 (en) Pharmaceutical composition for preventing or treating respiratory disease comprising extract of Justicia procumbens L.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2019001750A1 (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas.